Pfizer Inc. (PFE) EVP Rady A. Johnson Sells 8,000 Shares of Stock

Pfizer Inc. (NYSE:PFE) EVP Rady A. Johnson sold 8,000 shares of Pfizer stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares in the company, valued at approximately $1,740,918.41. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Pfizer Inc. (NYSE PFE) opened at $37.13 on Tuesday. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $221,320.00, a price-to-earnings ratio of 14.88, a P/E/G ratio of 2.62 and a beta of 1.01. Pfizer Inc. has a 1-year low of $30.90 and a 1-year high of $37.35.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.61 EPS. analysts anticipate that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.66%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is presently 78.53%.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of Pfizer by 2.3% during the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after buying an additional 9,239,499 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Pfizer by 4.4% during the third quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock valued at $2,136,189,000 after buying an additional 2,502,659 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Pfizer by 0.9% during the second quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock valued at $1,550,754,000 after buying an additional 389,629 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Pfizer by 4.8% during the second quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock valued at $1,487,617,000 after buying an additional 2,028,313 shares in the last quarter. Finally, Fisher Asset Management LLC grew its holdings in shares of Pfizer by 3.2% during the third quarter. Fisher Asset Management LLC now owns 35,120,799 shares of the biopharmaceutical company’s stock valued at $1,253,813,000 after buying an additional 1,085,437 shares in the last quarter. Institutional investors and hedge funds own 69.89% of the company’s stock.

Several brokerages have weighed in on PFE. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Tuesday, October 3rd. Vetr downgraded Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price on the stock. in a research note on Wednesday, September 13th. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Sanford C. Bernstein set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, September 19th. Finally, Deutsche Bank set a $38.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $38.77.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://sportsperspectives.com/2017/12/19/pfizer-inc-pfe-evp-rady-a-johnson-sells-8000-shares-of-stock.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Insider Buying and Selling by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply